Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Caredx Inc

Current price
9.87 USD +0.08 USD (+0.82%)
Last closed 9.88 USD
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 534 492 192 USD
Yield for 12 month -21.23 %
21.11.2021 - 28.11.2021

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California. Address: 1 Tower Place, South San Francisco, CA, United States, 94080


WallStreet Target Price

10.8 USD

P/E ratio

Dividend Yield

Current Year

+321 793 000 USD

Last Year

+296 397 000 USD

Current Quarter

+67 192 000 USD

Last Quarter

+70 301 000 USD

Current Year

+209 581 000 USD

Last Year

+199 008 000 USD

Current Quarter

+42 659 000 USD

Last Quarter

+44 414 000 USD

Key Figures CDNA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -84 342 000 USD
Operating Margin TTM -42.39 %
PE Ratio
Return On Assets TTM -11.75 %
PEG Ratio -0.12
Return On Equity TTM -21.79 %
Wall Street Target Price 10.8 USD
Revenue TTM 297 139 008 USD
Book Value 7.28 USD
Revenue Per Share TTM 5.52 USD
Dividend Share
Quarterly Revenue Growth YOY -15.3 %
Dividend Yield
Gross Profit TTM 209 581 000 USD
Earnings Share -1.69 USD
Diluted Eps TTM -1.69 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -30.46 %

Dividend Analytics CDNA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CDNA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CDNA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.0147
Price Sales TTM 1.7988
Enterprise Value EBITDA -3.7817
Price Book MRQ 1.3561

Financials CDNA

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CDNA

For 52 weeks

4.8 USD 18.04 USD
50 Day MA 7.11 USD
Shares Short Prior Month 4 503 397
200 Day MA 8.78 USD
Short Ratio 2.95
Shares Short 3 888 368
Short Percent 9.35 %